Evidence map›Paper›PMID 37386460›Full record

ArticleBMC gastroenterology2023

Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation.

Yandi Xie, Minghui Li, Xiaojuan Ou, Sujun Zheng, Yinjie Gao, Xiaoyuan Xu, Ying Yang, Anlin Ma, Jia Li, Yuemin Nan and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. [Research progress of biomarkers of hepatitis B virus and clinical significance].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yandi XieBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Peking University Hepatology Institute, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, 100044, China.
Minghui LiDepartment of Hepatology Division, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Xiaojuan OuLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Sujun ZhengComplicated Liver Diseases and Artificial Liver Treatment and Training Center, Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment and Research, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Yinjie GaoDepartment of Infectious Diseases, The Fifth Medical Center, General Hospital of PLA, Beijing, 100039, China.
Xiaoyuan XuDepartment of Infectious Diseases, Peking University First Hospital, Beijing, 100034, China.
Ying YangDepartment of Infectious Diseases, The Second Hospital of Xingtai, Xingtai, Hebei, 054001, China.
Anlin MaDepartment of Infectious Disease, Friendship Hospital, Beijing, 100029, China.
Jia LiDepartment of Liver Disease, Tianjin Second People's Hospital, Tianjin, 300192, China.
Yuemin NanDepartment of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050051, China.
Huanwei ZhengDepartment of Liver Disease, Shijiazhuang Fifth Hospital, Shijiazhuang, Hebei, 050021, China.
Juan LiuResearch Center for Technologies in Nucleic Acid-Based Diagnostics, Changsha, Hunan, 410205, China.
Lai WeiDepartment of Hepatopancreatobiliary Disease, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, China.
Bo FengBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Peking University Hepatology Institute, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, 100044, China. fengbo@pkuph.edu.cn.

Funding

Beijing Municipal Science and Technology Commission of Major Projects D161100002716002National Major Science and Technology Project of China 2017ZX10302201-004-001National Natural Science Foundation of China 82000557Peking University People's Hospital Research and Development Funds RDY2020-12
6 · The paper itself

Abstract

backgroundSince hepatitis B surface antigen (HBsAg) loss is rarely achieved with nucleos(t)ide analog (NA) treatment, most patients require life-long NA treatment. Previous studies have shown that some patients remain virologically responsive even after NA cessation. However, there is still controversy surrounding whether NA discontinuation increases the HBsAg loss rate. Therefore, this study aimed to assess the cumulative rate of HBsAg loss and identify the predictors of HBsAg loss after NA discontinuation.

methodsThis multicenter prospective study included HBV e antigen (HBeAg)-positive patients without cirrhosis from 12 hospitals in China who met the inclusion criteria. The enrolled patients stopped NA and were followed up with clinical and laboratory assessments every 3 months for 24 months after NA cessation or until clinical relapse (CR) occurred.

resultsOverall, 158 patients were classified into two groups. Group A included patients with HBsAg positivity at NA cessation (n = 139), and Group B included patients with HBsAg negativity at NA cessation (n = 19). In Group A, the 12-month and 24-month cumulative rates of HBsAg loss were4.3%and 9.4%, respectively. End of treatment (EOT) HBsAg (hazard ratio (HR) = 0.152, P < 0.001) and EOT hepatitis B core-related antigen (HBcrAg) (HR = 0.257, P = 0.001) were associated with HBsAg loss. The areas under the receiver operating characteristic curves for EOT HBsAg and HBcrAg levels were 0.952 (P < 0.001) and 0.765 (P < 0.001), respectively. Patients with EOT HBsAg ≤ 135 IU/mL (59.2% vs. 1.3%, P < 0.001) or HBcrAg ≤ 3.6 logU/mL (17% vs. 5.4%, P = 0.027) had a higher 24-month cumulative HBsAg loss rate. In Group B, none of the patients experienced virological relapse after NA cessation. Only 1 (5.3%) patient had HBsAg reversion.

conclusionsEOT HBsAg ≤ 135 IU/mL or HBcrAg ≤ 3.6 logU/mL can be used to identify patients with a higher likelihood of HBsAg loss after NA cessation. Patients with HBsAg negativity after NA cessation have favorable clinical outcomes, and HBsAg loss was durable in most cases.

Indexed as

Hepatitis B e AntigensHepatitis B Surface AntigensChinaHepatitis B Core AntigensHumansProspective StudiesHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensCessationHepatitis B core-related antigenHepatitis B surface antigenHepatitis B virus RNANucleos(t)ide analog

Identifiers

PMID37386460
PMCPMC10308768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.